VANDA PHARMACEUTICALS INC (VNDA)
US9216591084 - Common Stock
Overall VNDA gets a fundamental rating of 4 out of 10. We evaluated VNDA against 588 industry peers in the Biotechnology industry. VNDA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VNDA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
VNDA had positive earnings in the past year.
VNDA had a positive operating cash flow in the past year.
VNDA had positive earnings in each of the past 5 years.
In the past 5 years VNDA always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.39%, VNDA belongs to the top of the industry, outperforming 94.35% of the companies in the same industry.
VNDA has a Return On Equity of 0.46%. This is amongst the best in the industry. VNDA outperforms 94.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.39% | ||
| ROE | 0.46% | ||
| ROIC | N/A |
ROA(3y)2.32%
ROA(5y)7.05%
ROE(3y)2.74%
ROE(5y)8.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of VNDA (1.30%) is better than 94.86% of its industry peers.
In the last couple of years the Profit Margin of VNDA has declined.
VNDA has a better Gross Margin (92.31%) than 94.52% of its industry peers.
VNDA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 1.3% | ||
| GM | 92.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.23%
PM growth 5Y-36.93%
GM growth 3Y0.64%
GM growth 5Y0.65%
2. Health
2.1 Basic Checks
VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VNDA has been increased compared to 1 year ago.
VNDA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VNDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VNDA has an Altman-Z score of 2.07. This is not the best score and indicates that VNDA is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.07, VNDA is doing good in the industry, outperforming 72.26% of the companies in the same industry.
There is no outstanding debt for VNDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 2.07 |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
A Current Ratio of 4.94 indicates that VNDA has no problem at all paying its short term obligations.
The Current ratio of VNDA (4.94) is comparable to the rest of the industry.
VNDA has a Quick Ratio of 4.92. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
VNDA's Quick ratio of 4.92 is in line compared to the rest of the industry. VNDA outperforms 54.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.94 | ||
| Quick Ratio | 4.92 |
3. Growth
3.1 Past
VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.33%.
VNDA shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -36.12% yearly.
VNDA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.27%.
The Revenue has been decreasing by -0.05% on average over the past years.
EPS 1Y (TTM)-58.33%
EPS 3Y-51.19%
EPS 5Y-36.12%
EPS growth Q2Q-133.33%
Revenue 1Y (TTM)-24.27%
Revenue growth 3Y-8.1%
Revenue growth 5Y-0.05%
Revenue growth Q2Q-29.79%
3.2 Future
VNDA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -195.50% yearly.
Based on estimates for the next years, VNDA will show a small growth in Revenue. The Revenue will grow by 5.50% on average per year.
EPS Next Y-222.4%
EPS Next 2Y-195.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.48%
Revenue Next 2Y12.26%
Revenue Next 3Y-2.01%
Revenue Next 5Y5.5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VNDA is valuated quite expensively with a Price/Earnings ratio of 91.20.
Based on the Price/Earnings ratio, VNDA is valued cheaply inside the industry as 94.52% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.25. VNDA is valued rather expensively when compared to this.
VNDA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 91.2 | ||
| Fwd PE | N/A |
4.2 Price Multiples
96.75% of the companies in the same industry are more expensive than VNDA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.13 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VNDA has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as VNDA's earnings are expected to decrease with -195.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-195.5%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for VNDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VANDA PHARMACEUTICALS INC
NASDAQ:VNDA (4/24/2024, 4:41:14 PM)
After market: 4.56 0 (0%)4.56
-0.07 (-1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap262.38M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 91.2 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.39% | ||
| ROE | 0.46% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 1.3% | ||
| GM | 92.31% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.94 | ||
| Quick Ratio | 4.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-58.33%
EPS 3Y-51.19%
EPS 5Y
EPS growth Q2Q
EPS Next Y-222.4%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-24.27%
Revenue growth 3Y-8.1%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y